PMID- 17151862 OWN - NLM STAT- MEDLINE DCOM- 20070926 LR - 20220410 IS - 0012-186X (Print) IS - 0012-186X (Linking) VI - 50 IP - 2 DP - 2007 Feb TI - Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. PG - 431-8 AB - AIMS/HYPOTHESIS: Decreased levels of brain-derived neurotrophic factor (BDNF) have been implicated in the pathogenesis of Alzheimer's disease and depression. These disorders are associated with type 2 diabetes, and animal models suggest that BDNF plays a role in insulin resistance. We therefore explored whether BDNF plays a role in human glucose metabolism. SUBJECTS AND METHODS: We included (Study 1) 233 humans divided into four groups depending on presence or absence of type 2 diabetes and presence or absence of obesity; and (Study 2) seven healthy volunteers who underwent both a hyperglycaemic and a hyperinsulinaemic-euglycaemic clamp. RESULTS: Plasma levels of BDNF in Study 1 were decreased in humans with type 2 diabetes independently of obesity. Plasma BDNF was inversely associated with fasting plasma glucose, but not with insulin. No association was found between the BDNF G196A (Val66Met) polymorphism and diabetes or obesity. In Study 2 an output of BDNF from the human brain was detected at basal conditions. This output was inhibited when blood glucose levels were elevated. In contrast, when plasma insulin was increased while maintaining normal blood glucose, the cerebral output of BDNF was not inhibited, indicating that high levels of glucose, but not insulin, inhibit the output of BDNF from the human brain. CONCLUSIONS/INTERPRETATION: Low levels of BDNF accompany impaired glucose metabolism. Decreased BDNF may be a pathogenetic factor involved not only in dementia and depression, but also in type 2 diabetes, potentially explaining the clustering of these conditions in epidemiological studies. FAU - Krabbe, K S AU - Krabbe KS AD - The Centre of Inflammation and Metabolism, Department of Infectious Diseases, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. karen.krabbe@dadlnet.dk FAU - Nielsen, A R AU - Nielsen AR FAU - Krogh-Madsen, R AU - Krogh-Madsen R FAU - Plomgaard, P AU - Plomgaard P FAU - Rasmussen, P AU - Rasmussen P FAU - Erikstrup, C AU - Erikstrup C FAU - Fischer, C P AU - Fischer CP FAU - Lindegaard, B AU - Lindegaard B FAU - Petersen, A M W AU - Petersen AM FAU - Taudorf, S AU - Taudorf S FAU - Secher, N H AU - Secher NH FAU - Pilegaard, H AU - Pilegaard H FAU - Bruunsgaard, H AU - Bruunsgaard H FAU - Pedersen, B K AU - Pedersen BK LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20061207 PL - Germany TA - Diabetologia JT - Diabetologia JID - 0006777 RN - 0 (Blood Glucose) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Insulin) RN - 9007-41-4 (C-Reactive Protein) RN - 9007-49-2 (DNA) SB - IM CIN - Diabetologia. 2007 Aug;50(8):1781-2. PMID: 17546439 CIN - Diabetologia. 2007 Sep;50(9):2027-8; author reply 2029-30. PMID: 17634920 MH - Adult MH - Blood Glucose/drug effects/metabolism MH - Brain-Derived Neurotrophic Factor/blood/genetics/*physiology MH - C-Reactive Protein/metabolism MH - Cardiovascular Diseases/blood MH - Cross-Sectional Studies MH - DNA/genetics/isolation & purification MH - Diabetes Mellitus, Type 2/*blood/epidemiology/genetics MH - Diabetic Angiopathies/blood MH - Glucose Clamp Technique MH - Glucose Tolerance Test MH - Humans MH - Insulin/pharmacology MH - Insulin Resistance MH - Male MH - Polymerase Chain Reaction MH - Polymorphism, Single Nucleotide MH - Reference Values EDAT- 2006/12/08 09:00 MHDA- 2007/09/27 09:00 CRDT- 2006/12/08 09:00 PHST- 2006/06/27 00:00 [received] PHST- 2006/10/19 00:00 [accepted] PHST- 2006/12/08 09:00 [pubmed] PHST- 2007/09/27 09:00 [medline] PHST- 2006/12/08 09:00 [entrez] AID - 10.1007/s00125-006-0537-4 [doi] PST - ppublish SO - Diabetologia. 2007 Feb;50(2):431-8. doi: 10.1007/s00125-006-0537-4. Epub 2006 Dec 7.